Skip to content

News & Events

Academic Breast Cancer Consortium (ABRCC)​

Explore ABRCC

ABRCC Home
Institutions & Investigators
About
Facts
Publications

Explore Oncology Consortia

GI Cancer (AGICC)
Myeloma (AMyC)
Thoracic Oncology (ATOMIC)
GU Cancer (AURIC)
Understanding Breast Cancer: Statistics and Insights
Breast cancer remains a significant health concern worldwide, affecting millions of women and men each year. Learn more with this overview of breast cancer statistics for 2024, highlighting key facts and figures to raise awareness and promote early detection. 
Dr. D. Ross Camidge and Dr. Peter Kabos Win University of Colorado Recognition Awards
Dr. Peter Kabos, MD, Associate Professor, Division of Medical Oncology and Dr. D. Ross Camidge, MD, PhD, Professor of Medicine/Oncology were recently honored by the University of Colorado’s Division of Medical Oncology.
PharmaVoice Interview with Dr. Peter Kabos, Director of the Academic Breast Cancer Consortium (ABRCC)
Watch this PharmaVoice One on One video interview to learn more about the latest in breast cancer research from Dr. Peter Kabos, Director of the Academic Breast Cancer Consortium and Assistant Professor in the Division of Medical Oncology at University of Colorado Cancer Center.
What’s New in Breast Cancer Research and Treatment?
Criterium's Academic Breast Cancer Consortium (ABRCC) is comprised of 15 renowned academic and community sites in North America, conducting translational research in Breast Cancer studies for major pharmaceutical companies who are working on the most current clinical trials for advanced treatments of breast cancer. While 2020 was a year dominated by COVID-19 news and tragedy, breast cancer research and breakthroughs can't wait for COVID to "go away" – and research in this area continues on full-speed. Our ABRCC researchers reflect on 2020 and look ahead to 2021 with renewed hope.
Following NCCN Guidelines for Metastatic Breast Cancer Results in Lower Costs for Patients
Research from the O’Neal Comprehensive Cancer Center at UAB finds patients treated outside of NCCN Guidelines recommendations had significantly higher direct costs. A new study from the O’Neal Comprehensive Cancer Center at University of Alabama at Birmingham (UAB), published in the October 2019 issue of JNCCN—Journal of the National Comprehensive Cancer
« Prev12Next »